Cartherics is delighted to announce that Saleh Almasabi has successfully completed his PhD Candidature.
Saleh’s research thesis, ‘The role of integrin linked kinase in senescence and immunosuppressive tumor microenvironment in colon cancer’, identified that integrin-linked kinase (ILK) is associated with cancer prognosis and characterises the immunosuppressive tumor microenvironment. These findings suggest possible clinical avenues of targeting […]
Melbourne, Australia, 09 January 2023 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted Chinese patent ZL 201680069543.6, entitled “Genetically modified cells and uses thereof”. This patent is part of the family represented by the international patent filing WO2017088012.
The […]
Melbourne, Victoria, Australia – 08 November 2022
The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma (CTCL).
“Patients with advanced stages of cutaneous T-cell lymphomas often […]
Cartherics is delighted to be participating in Frocktober – Australia’s most fashionable month-long fundraiser to raise awareness and funds for vital ovarian cancer research through the Ovarian Cancer Research Foundation (OCRF).
Ovarian cancer is Australia’s most lethal gynaecological cancer, taking more than 1,000 lives each year. With a five-year survival rate of only 48%, there […]
MELBOURNE, Australia, 13 October 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, has opened today a brand-new state-of-the-art facility to strengthen the company’s research and manufacturing capabilities, as well as support local innovation. Cartherics invested AU$4M in the newly designed and built facility, which includes PC2 and dedicated […]
Melbourne, Australia, 06 October 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted US patent 11,400,145, entitled “Genetically modified cells and uses thereof”.
This patent provides a proprietary position for multiple development candidates in Cartherics’ pipeline. Specifically, this patent covers Cartherics’ chimeric […]
By Leigh Dayton, 16 June 2022
Cartherics is delighted to announce that Non-Executive Director Bryan Williams is one of the top 1000 scientists worldwide in the field of Genetics and Molecular Biology, according to Research.com, a prominent academic platform for scientists.
In the recently released edition its […]
By Leigh Dayton 9 June 2022
It’s official. As of this month, ovarian cancer campaigner Heather Hawkins takes up her role as an Advisory Board Member for Cartherics.
“It’s a privilege and an honour to be part of the Board,” she says. “And I’m looking forward to assisting […]
Chief Development Officer, Dr Nicholas Boyd
Cell therapies have the potential to not only be life-saving but curative for a host of diseases. However, inherent limitations in autologous based CAR-T therapy face major roadblocks for mass adoption and therapeutic effects in solid tumour indications.
On Friday 28 January at 7:30 am AEDT Nicholas will discuss the design, […]
By Leigh Dayton, 17 January 2022
Cellular immunotherapy is revolutionizing cancer treatment, and off-the-shelf or allogeneic, treatments are beginning to replace technologies developed individually for each patient.
This is good news because the potential of allogeneic therapies is great. They promise to significantly save time and cut costs compared […]
Cartherics’ mission is the development of novel, “off-the-shelf” (allogeneic) immune cell therapy products for the treatment of cancer.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
